LYZ

Across TCGA pan-cancer cohorts, LYZ RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of LYZ’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LYZ RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LYZ is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

KIRC, LUSC, and LUAD are the cancer types where LYZ tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LYZ RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+3.048	<.001	12	view →
LUSC	Male	III,IV	−3.150	<.001	8	view →
LUAD	Female	III,IV	−2.138	<.001	8	view →
HNSC	All	All	−1.946	<.001	8	view →
THCA	Male	IV	+5.520	<.001	6	view →
BRCA	Female	All	+1.089	<.001	6	view →
KIRP	Male	All	+1.912	<.001	5	view →
LIHC	All	II,III,IV	+1.752	.004	4	view →
STAD	All	All	+2.189	.005	3	view →
CHOL	All	All	+2.834	.003	2	view →
KICH	All	II,III,IV	−1.402	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

LYZ–KIRC

Open the KIRC breakdown →